NanoViricides Historical Balance Sheet

NNVC Stock

USD 1.75 0.05 2.94%

Trend analysis of NanoViricides balance sheet accounts such as Accounts Payable of 260.7 K provides information on NanoViricides' total assets, liabilities, and equity, which is the actual value of NanoViricides to its prevalent stockholders. By breaking down trends over time using NanoViricides balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining NanoViricides latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether NanoViricides is a good buy for the upcoming year.

Build AI portfolio with NanoViricides Stock

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NanoViricides. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.

About NanoViricides Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of NanoViricides at a specified time, usually calculated after every quarter, six months, or one year. NanoViricides Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of NanoViricides and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which NanoViricides currently owns. An asset can also be divided into two categories, current and non-current.

NanoViricides Balance Sheet Chart

At present, NanoViricides' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Common Stock Shares Outstanding is expected to grow to about 14.3 M, whereas Other Current Liabilities is forecasted to decline to about 691.7 K.

Other Current Liab Total Current Liabilities Accounts Payable Common Stock Total Equity

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on NanoViricides balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of NanoViricides are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents NanoViricides obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of NanoViricides are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Most accounts from NanoViricides' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into NanoViricides current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NanoViricides. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.At present, NanoViricides' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Common Stock Shares Outstanding is expected to grow to about 14.3 M, whereas Other Current Liabilities is forecasted to decline to about 691.7 K.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	534.3K	1.4M	1.6M	1.7M
Other Current Liabilities	377.2K	982.5K	1.1M	691.7K

Total Current Liabilities Other Current Liab

NanoViricides balance sheet Correlations

	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Common Stock	Total Assets	Short Long Term Debt Total	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Preferred Stock Total Equity	Property Plant Equipment	Net Tangible Assets
Other Current Liab		0.13	-0.29	-0.02	0.57	0.33	-0.14	-0.01	-0.05	0.3	-0.26	-0.09	-0.07	0.28	-0.27	-0.05	0.27	-0.27	0.01	0.07	-0.06	-0.27	0.36	0.27	-0.08	-0.49
Total Current Liabilities	0.13		0.11	0.06	-0.04	0.15	-0.28	-0.04	0.43	0.16	0.26	0.27	0.39	0.0	0.14	0.4	-0.06	0.14	0.09	-0.09	0.13	0.14	0.31	0.15	0.38	-0.01
Total Stockholder Equity	-0.29	0.11		-0.21	-0.07	-0.27	0.04	0.3	0.47	-0.22	0.92	0.54	0.61	-0.85	0.81	0.64	0.0	0.81	0.43	-0.36	0.29	0.8	0.55	-0.33	0.57	0.9
Retained Earnings	-0.02	0.06	-0.21		-0.32	0.81	-0.86	-0.96	0.4	0.83	0.04	0.5	-0.54	-0.21	0.29	-0.52	0.56	0.29	0.57	0.07	-0.86	0.29	-0.27	0.84	-0.58	-0.13
Accounts Payable	0.57	-0.04	-0.07	-0.32		-0.22	0.19	0.32	-0.03	-0.24	-0.08	-0.22	-0.07	0.08	-0.1	-0.04	0.26	-0.1	0.01	0.04	0.07	-0.09	0.37	-0.28	-0.05	-0.19
Common Stock Total Equity	0.33	0.15	-0.27	0.81	-0.22		-0.77	-0.81	0.14	1.0	-0.14	0.3	-0.42	-0.03	0.06	-0.43	0.48	0.06	0.36	0.0	-0.71	0.06	-0.11	0.99	-0.47	-0.29
Common Stock Shares Outstanding	-0.14	-0.28	0.04	-0.86	0.19	-0.77		0.89	-0.5	-0.8	-0.18	-0.56	0.19	0.27	-0.35	0.17	-0.46	-0.35	-0.56	-0.04	0.76	-0.35	0.04	-0.79	0.27	0.11
Other Stockholder Equity	-0.01	-0.04	0.3	-0.96	0.32	-0.81	0.89		-0.31	-0.83	0.08	-0.39	0.54	0.13	-0.19	0.53	-0.52	-0.19	-0.48	-0.17	0.9	-0.2	0.33	-0.85	0.6	0.27
Total Liab	-0.05	0.43	0.47	0.4	-0.03	0.14	-0.5	-0.31		0.16	0.78	0.89	0.16	-0.67	0.82	0.23	0.46	0.82	0.88	-0.24	-0.17	0.82	0.4	0.12	0.12	0.4
Common Stock	0.3	0.16	-0.22	0.83	-0.24	1.0	-0.8	-0.83	0.16		-0.09	0.33	-0.4	-0.08	0.1	-0.4	0.48	0.1	0.38	0.02	-0.73	0.1	-0.1	0.99	-0.45	-0.25
Total Assets	-0.26	0.26	0.92	0.04	-0.08	-0.14	-0.18	0.08	0.78	-0.09		0.78	0.49	-0.9	0.93	0.54	0.19	0.93	0.69	-0.39	0.14	0.93	0.53	-0.18	0.45	0.84
Short Long Term Debt Total	-0.09	0.27	0.54	0.5	-0.22	0.3	-0.56	-0.39	0.89	0.33	0.78		0.2	-0.72	0.83	0.25	0.36	0.83	0.88	-0.44	-0.18	0.82	0.32	0.28	0.16	0.51
Property Plant And Equipment Net	-0.07	0.39	0.61	-0.54	-0.07	-0.42	0.19	0.54	0.16	-0.4	0.49	0.2		-0.18	0.19	1.0	-0.62	0.19	-0.15	-0.49	0.71	0.18	0.37	-0.43	0.99	0.5
Net Debt	0.28	0.0	-0.85	-0.21	0.08	-0.03	0.27	0.13	-0.67	-0.08	-0.9	-0.72	-0.18		-0.97	-0.23	-0.44	-0.97	-0.77	0.2	0.18	-0.97	-0.45	0.03	-0.11	-0.76
Cash	-0.27	0.14	0.81	0.29	-0.1	0.06	-0.35	-0.19	0.82	0.1	0.93	0.83	0.19	-0.97		0.25	0.45	1.0	0.85	-0.26	-0.18	1.0	0.43	0.01	0.13	0.74
Non Current Assets Total	-0.05	0.4	0.64	-0.52	-0.04	-0.43	0.17	0.53	0.23	-0.4	0.54	0.25	1.0	-0.23	0.25		-0.56	0.25	-0.09	-0.46	0.69	0.24	0.43	-0.45	0.98	0.51
Non Currrent Assets Other	0.27	-0.06	0.0	0.56	0.26	0.48	-0.46	-0.52	0.46	0.48	0.19	0.36	-0.62	-0.44	0.45	-0.56		0.45	0.72	0.38	-0.67	0.46	0.37	0.41	-0.68	-0.15
Cash And Short Term Investments	-0.27	0.14	0.81	0.29	-0.1	0.06	-0.35	-0.19	0.82	0.1	0.93	0.83	0.19	-0.97	1.0	0.25	0.45		0.85	-0.26	-0.18	1.0	0.43	0.01	0.13	0.74
Non Current Liabilities Total	0.01	0.09	0.43	0.57	0.01	0.36	-0.56	-0.48	0.88	0.38	0.69	0.88	-0.15	-0.77	0.85	-0.09	0.72	0.85		-0.18	-0.42	0.85	0.36	0.31	-0.21	0.36
Other Current Assets	0.07	-0.09	-0.36	0.07	0.04	0.0	-0.04	-0.17	-0.24	0.02	-0.39	-0.44	-0.49	0.2	-0.26	-0.46	0.38	-0.26	-0.18		-0.41	-0.25	0.1	-0.01	-0.52	-0.56
Property Plant And Equipment Gross	-0.06	0.13	0.29	-0.86	0.07	-0.71	0.76	0.9	-0.17	-0.73	0.14	-0.18	0.71	0.18	-0.18	0.69	-0.67	-0.18	-0.42	-0.41		-0.18	0.25	-0.72	0.78	0.29
Total Current Assets	-0.27	0.14	0.8	0.29	-0.09	0.06	-0.35	-0.2	0.82	0.1	0.93	0.82	0.18	-0.97	1.0	0.24	0.46	1.0	0.85	-0.25	-0.18		0.43	0.01	0.13	0.73
Intangible Assets	0.36	0.31	0.55	-0.27	0.37	-0.11	0.04	0.33	0.4	-0.1	0.53	0.32	0.37	-0.45	0.43	0.43	0.37	0.43	0.36	0.1	0.25	0.43		-0.23	0.33	0.2
Preferred Stock Total Equity	0.27	0.15	-0.33	0.84	-0.28	0.99	-0.79	-0.85	0.12	0.99	-0.18	0.28	-0.43	0.03	0.01	-0.45	0.41	0.01	0.31	-0.01	-0.72	0.01	-0.23		-0.47	-0.31
Property Plant Equipment	-0.08	0.38	0.57	-0.58	-0.05	-0.47	0.27	0.6	0.12	-0.45	0.45	0.16	0.99	-0.11	0.13	0.98	-0.68	0.13	-0.21	-0.52	0.78	0.13	0.33	-0.47		0.5
Net Tangible Assets	-0.49	-0.01	0.9	-0.13	-0.19	-0.29	0.11	0.27	0.4	-0.25	0.84	0.51	0.5	-0.76	0.74	0.51	-0.15	0.74	0.36	-0.56	0.29	0.73	0.2	-0.31	0.5

Click cells to compare fundamentals

NanoViricides Account Relationship Matchups

NanoViricides balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Other Current Liab	55.8K	260.1K	377.2K	982.5K	1.1M	691.7K
Total Current Liabilities	351.1K	412.8K	534.3K	1.4M	1.6M	1.7M
Total Stockholder Equity	29.9M	23.1M	14.9M	11.5M	13.2M	15.2M
Retained Earnings	(114.4M)	(122.5M)	(131.1M)	(139.4M)	(125.4M)	(119.2M)
Accounts Payable	200.0K	58.0K	157.1K	376.3K	338.6K	260.7K
Common Stock Shares Outstanding	10.9M	11.5M	11.6M	11.9M	13.7M	14.3M
Other Stockholder Equity	144.3M	145.6M	145.9M	150.8M	173.5M	182.1M
Total Liab	351.1K	412.8K	2.0M	1.4M	1.6M	1.5M
Accumulated Other Comprehensive Income	(3.9M)	(4.6M)	(5.0)	(9.0)	(8.1)	(8.51)
Common Stock	11.5K	11.6K	116.0	131.0	117.9	112.01
Total Assets	30.3M	23.5M	16.9M	12.8M	14.7M	20.4M
Property Plant And Equipment Net	9.1M	8.7M	8.1M	7.5M	8.6M	6.3M
Net Debt	(20.4M)	(14.0M)	(8.1M)	(4.8M)	(4.3M)	(4.5M)
Cash	20.5M	14.1M	8.1M	4.8M	5.5M	5.2M
Non Current Assets Total	9.4M	9.1M	8.5M	7.9M	9.0M	6.8M
Non Currrent Assets Other	3.5K	42.4K	14.4K	14.6K	13.1K	12.5K
Cash And Short Term Investments	20.5M	14.1M	8.1M	4.8M	5.5M	5.2M
Liabilities And Stockholders Equity	30.3M	23.5M	16.9M	12.8M	14.7M	20.4M
Non Current Liabilities Total	309.9K	1.5M	295.3K	152.7K	1.5M	0.0
Other Current Assets	307.1K	350.0K	295.5K	172.7K	155.5K	220.2K
Property Plant And Equipment Gross	9.1M	14.7M	14.8M	15.0M	17.2M	18.1M
Total Current Assets	20.8M	14.4M	8.4M	5.0M	5.7M	5.4M
Intangible Assets	350.1K	341.8K	333.6K	325.3K	374.1K	357.5K
Property Plant Equipment	9.5M	9.1M	8.7M	8.1M	9.3M	8.4M
Net Tangible Assets	21.4M	29.6M	22.7M	14.5M	16.7M	22.0M
Net Invested Capital	30.0M	23.2M	14.9M	11.5M	10.3M	15.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

VALE	Vale SA ADR
EGY	Vaalco Energy
CMCSA	Comcast Corp

When determining whether NanoViricides offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NanoViricides' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nanoviricides Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nanoviricides Stock:

How To Invest In NanoViricides

Details

Is NanoViricides Stock a good investment?

Details

What is NanoViricides' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.

You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NanoViricides. If investors know NanoViricides will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NanoViricides listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.69)

Return On Assets

(0.57)

Return On Equity

(1.00)

The market value of NanoViricides is measured differently than its book value, which is the value of NanoViricides that is recorded on the company's balance sheet. Investors also form their own opinion of NanoViricides' value that differs from its market value or its book value, called intrinsic value, which is NanoViricides' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NanoViricides' market value can be influenced by many factors that don't directly affect NanoViricides' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NanoViricides' value and its price as these two are different measures arrived at by different means. Investors typically determine if NanoViricides is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NanoViricides' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

NanoViricides Historical Balance Sheet

About NanoViricides Balance Sheet Analysis

NanoViricides Balance Sheet Chart

Total Current Liabilities

Accounts Payable

Common Stock Total Equity

NanoViricides balance sheet Correlations

NanoViricides Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NanoViricides balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Preferred Stock Total Equity	+ 0.99	Common Stock Total Equity

Total Current Assets	- 0.97	Net Debt
Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Net Debt	- 0.9	Total Assets
Property Plant And Equipment Gross	- 0.86	Retained Earnings